232 Research news
Memory Problems After Chemotherapy Linked to Changes in Brain Activity

A small study suggests that changes in brain activity may be the cause of chemo brain.

Jun 24, 2014 | Diagnosis, Chemotherapy and Side Effects
Immunotherapy for Early-Stage Triple-Negative Breast Cancer: Understanding What Appear to Be Conflicting Results

Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not.

More Evidence That Chemotherapy Before Surgery Can Make Triple-Negative Breast Cancer Eligible for Lumpectomy

About half of women diagnosed with early-stage triple-negative breast cancer who were not eligible for lumpectomy when first diagnosed became eligible for lumpectomy after neoadjuvant chemotherapy.

Triple-Negative Disease May Have New Treatment Option

Two studies presented at the 2015 San Antonio Breast Cancer Symposium suggest that adding carboplatin to the standard neoadjuvant chemotherapy regimen may improve outcomes for women diagnosed with triple-negative disease.

Dec 10, 2015 | Diagnosis and Chemotherapy
Treating Residual Disease With Xeloda Improves Survival in Women With Early-Stage, HER2-Negative Disease

Women diagnosed with early-stage, HER2-negative breast cancer with residual disease who were treated with Xeloda after surgery had better survival compared to women who didn't get chemotherapy after surgery.

Dec 22, 2015 | Diagnosis and Chemotherapy
Treating Inflammatory Breast Cancer With Surgery, Chemotherapy, and Radiation Improves Survival

A study has found that women diagnosed with inflammatory breast cancer who are treated with chemotherapy, surgery, and radiation have better survival rates than women who don't receive all three treatments.

Chemotherapy for Breast Cancer May Increase Risk of Common Infections

Women diagnosed with breast cancer who were treated with chemotherapy had lower levels of immune system cells for at least 9 months after chemotherapy ended.

Jan 27, 2016 | Diagnosis and Chemotherapy
Women Older Than 80 Less Likely to Benefit From Chemotherapy

A study has found that women older than 80 diagnosed with early-stage, hormone-receptor-negative breast cancer don't get survival benefits from chemotherapy.

Aug 18, 2015 | Diagnosis and Chemotherapy
"Heart Healthy" Lifestyle Important for Survivors

Researchers urge women who have had breast cancer treatment to keep their heart health in mind as they build long-term health.

Triple-Negative Breast Cancer's Response to Carboplatin Before Surgery Seems Affected By BRCA1/2 Mutation Status

In the GeparSixto study, women with a BRCA1 or BRCA2 mutation responded better to chemotherapy before surgery without carboplatin, while women without a mutation had better outcomes when carboplatin was added to the chemotherapy regimen.

Jul 14, 2017 | Diagnosis and Chemotherapy
Some Older Women With Early-Stage Hormone-Receptor-Positive, Node-Positive Breast Cancer Can Skip Chemotherapy

Postmenopausal women diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive lymph nodes and an Oncotype DX Recurrence Score of 25 or lower being treated with hormonal therapy after surgery can safely skip chemotherapy.

Taxotere Combo Improves Survival

The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.

Dec 13, 2007 | Diagnosis and Chemotherapy
Avastin Doesn't Affect Overall Survival

Avastin combined with Taxol lengthens the time until advanced breast cancer progresses, but doesn't improve overall survival.

Taxol Weekly Better Than Every Three Weeks for Breast Cancer

Getting Taxol (chemical name: placlitaxel) every week seems to have more benefits than getting it every 3 weeks or getting Taxotere (chemical name: docetaxel) on either schedule.

Apr 17, 2008 | Diagnosis and Chemotherapy
If Cancer Stops Responding to Herceptin, It May Have Switched From HER2-Positive to HER2-Negative

A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.

Factors Besides Treatment Likely Contribute to Survivors' Bone Loss

A small study shows that other factors besides breast cancer treatment contribute to bone loss in post-menopausal women.

New Chemo Meds Improve Survival for Women With Advanced-Stage Disease

Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.

Avastin Doesn't Improve Survival in Metastatic Breast Cancer

The FDA is considering whether to continue the approval for using Avastin with Taxol to treat metastatic breast cancer, as well as whether to approve it in combination with other medicines.

Older Women More Likely to Have Chemo-Related Cognitive Problems

Being older and having lower cognitive reserve levels may increase the risk of cognitive problems during and after chemotherapy.

Menopausal Symptoms, Chemo Side Effects Linked to Lower Quality of Life

Lower quality of life during and after breast cancer treatment seems to be closely linked to two factors: menopausal symptoms and chemotherapy side effects.

Chemo and Radiation Before Surgery Seems to Reduce Risk of Recurrence for Certain Breast Cancers

Research suggests that giving BOTH chemotherapy and radiation therapy before surgery to remove locally advanced breast cancer can help reduce the risk of the cancer coming back in the breast area in the 5 years after surgery.

Herceptin Plus Taxol Seems to Reduce Recurrence Risk of Small HER2-Positive Cancers

A small, early study suggests that a combination of Herceptin and Taxol seemed to reduce the risk of recurrence of small HER2-positive breast cancers that hadn't spread to the lymph nodes.

Avastin Added to Chemo Before Surgery Offers No Benefit

Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.

Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease

Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.

Showing 24 of 232